ONWARD Medical Shares Progress with Q1 2024 Report and Strategic Milestones

ONWARD Medical N.V., a pioneer in medical technology, has unveiled its performance and strategic achievements for the first quarter of 2024. The period was marked by significant milestones, including the publication of its Up-LIFT pivotal trial results in the esteemed journal Nature Medicine, the filing of an FDA De Novo application for its innovative ARC-EX® System, and the successful acquisition of EUR 20 million in equity capital.

Publication in Renowned Medical Journal

ONWARD Medical recently celebrated the publication of its Up-LIFT trial results in Nature Medicine, a notable event that underscores the trial's impact and the significance of its findings in the therapeutic landscape.

Regulatory Advancements

In a decisive step toward commercialization in the United States, ONWARD Medical submitted a De Novo application to the FDA for the ARC-EX® System, indicating the unique nature and potential benefit of this medical device for patients.

Capital Investment Success

Further fortifying its financial position, ONWARD Medical has reported the successful closing of a EUR 20 million equity funding round. This influx of capital is set to support the company's continued growth and innovation in the medical technology space.

Eindhoven-Based Company's Outlook

Based in Eindhoven, the Netherlands, ONWARD Medical N.V. is at the forefront of technological advancements in medicine. The company's progress and strategic direction as of May 23, 2024, have been covered by GLOBE NEWSWIRE, highlighting its commitment to enhancing patient outcomes.

NatureMedicine, FDADeNovo, CapitalRaising